Although several predictive biomarkers have been identified for cisplatin, such as ERCC1 [7], BRCA1 [4], [26], [27] and XRCC1 [28]–[30], considering the relatively low response rates of the commonly used platinum/5FU-based neoadjuvant treatment protocol for advanced gastric carcinoma patients, the identification of biomarkers to predict response is urgently needed. Here, ERCC1 is linked to gastric carcinoma.